SI-BONE Inc
Jeryl Lynn Hilleman is a member of the Board of Directors. In addition to SI-BONE, Inc., her current board positions include public companies Novocure (Nasdaq: NVCR) and Minerva Neurosciences (Nasdaq: NERV) as well as private companies Omada Health, where she is Chair of the Board, and Reiter Affiliated Companies. Ms. Hilleman has considerable tenure as an Audit Committee Chair and also serves on nominating and governance, compensation and pricing and transaction committees.
As a public company CFO for over 20 years, Ms. Hilleman was responsible for raising over one billion dollars in equity and debt financings including completing five initial public offerings and several M&A transactions. Her experience spans biopharmaceuticals, medical devices, instrument, and industrial companies.
Ms. Hilleman participated in the Medical Sciences program at Brown University and earned an M.B.A. from the Wharton School of Business. She is a member of the 1999 class of the Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute and has been recognized by several annual Silicon Valley award programs for her contributions as a CFO and as a female business leader.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
SI-BONE Inc
2 followers
SI-BONE, Inc. is focused on development of medical devices. The Company is engaged in the development, manufacture and commercialization of minimally invasive surgical devices for the treatment of patients with low back symptoms related to certain sacroiliac (SI) joint disorders. The Company offers iFuse Implant System, which provides a minimally invasive surgical solution to fuse the SI joint using patented triangular titanium implants that create an interference fit within the ilium and sacrum. The triangular implant shape, combined with the press fit insertion, is designed to provide fixation by minimizing rotational motion. The implants has a porous surface that provide an environment for bone ongrowth and ingrowth, facilitating long-term fusion of the joint. The iFuse Implant System is intended for sacroiliac fusion for conditions, including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis.